Donate now, support IFFGD

My Cart | Register | Sign In

Header Image

FDA Urged to Consider Patients First

For Immediate Release

Media Contact

Contact Go»

Milwaukee, WI (March 22, 2001) - Responding to comments by a consumer activist organization to end drug development of a treatment for irritable bowel syndrome (IBS), Nancy Norton, President and Founder of the International Foundation for Functional Gastrointestinal Disorders (IFFGD), today urged the FDA not to lose sight of the patients.

"The medical community has been slow in recognizing IBS as a legitimate disease. We are very concerned that 30 million Americans, mostly women, will be again forgotten by the medical system. IBS is a leading cause of absenteeism from work in the United States, costing the U.S. healthcare system over $8 billion a year.

"We urge the FDA to consider the patients first in making a decision on treatments for this devastating disease," says Norton.

More Information

For more information contact IFFGD at 414-964-1799.


Last modified on February 29, 2008 at 10:27:11 AM